SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback